Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | PDE6D | O43924 | 1/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.60 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | AKT1 | P31749 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL697201 | 1.00 | HMGCR (0.62) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL10305922 | 0.89 | HMGCR (0.64) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL696979 | 0.89 | HMGCR (0.64) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL696978 | 0.89 | HMGCR (0.64) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL10129259 | 0.89 | HMGCR (0.48) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL13538 | 0.89 | HMGCR (0.61) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL12074037 | 0.88 | HMGCR (0.68) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL8193721 | 0.88 | HMGCR (0.63) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL18269414 | 0.86 | HMGCR (0.62) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL22604013 | 0.86 | HMGCR (0.61) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576518-B1 | IMPROVED PROCESS FOR THE PREPARATION OF PROPENAL INTERMEDIATE AND DERIVATIVES THEREOF | PHARMATHEN SA (GR) | 2016-08-10 | — | — | EP | claimed |
| US-8575343-B2 | Process for the preparation of a propenal intermediate and derivatives thereof | PHARMATHEN S.A. (GR) | 2013-11-05 | — | — | US | claimed |
| US-20130066074-A1 | PROCESS FOR THE PREPARATION OF PROPENAL INTERMEDIATE AND DERIVATIVES THEREOF | PHARMATHEN S.A. (GR) | 2013-03-14 | — | — | US | claimed |
| US-8394956-B2 | Process for preparing pyrimidine propenaldehyde | AUROBINDO PHARMA LTD. (IN) | 2013-03-12 | — | — | US | claimed |
| US-8212034-B2 | Process for preparing rosuvastatin calcium | AUROBINDO PHARMA LTD. (IN) | 2012-07-03 | — | — | US | claimed |
| US-8049010-B2 | Using 4-4'-fluorophenyl-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-formaldehyde as raw material; cyanation to 4-4'-fluorophenyl-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-acrylonitrile; carbonylation, chain extension, hydrolysis, neutralization, decomposition, catalysis | Anhui Qingyun Pharmaceuticals & Chemical Co., Ltd. (CN) | 2011-11-01 | — | — | US | claimed |
| EP-2350025-A1 | AN IMPROVED PROCESS FOR PREPARING PYRIMIDINE PROPENALDEHYDE | Aurobindo Pharma Limited (IN) | 2011-08-03 | — | — | EP | claimed |
| US-20110178296-A1 | Process for preparing pyrimidine propenaldehyde | MALLELA SAMBHU PRASAD SARMA | 2011-07-21 | — | — | US | claimed |
| US-20100228028-A1 | PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES | ASTRAZENECA UK LIMITED (GB) | 2010-09-09 | — | — | US | claimed |
| WO-2010038124-A1 | AN IMPROVED PROCESS FOR PREPARING PYRIMIDINE PROPENALDEHYDE | AUROBINDO PHARMA LIMITED (IN) | 2010-04-08 | — | — | WO | claimed |
| US-20100029940-A1 | PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | AUROBINDO PHARMA LTD (IN) | 2010-02-04 | — | — | US | claimed |
| WO-2008072078-A1 | AN IMPROVED PROCESS FOR PREPARING ROSUVASTATIN CACLIUM | AUROBINDO PHARMA LIMITED (IN) | 2008-06-19 | — | — | WO | claimed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| WO-2008072078-A1 | AN IMPROVED PROCESS FOR PREPARING ROSUVASTATIN CACLIUM | AUROBINDO PHARMA LIMITED (IN) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008072078-A1 | AN IMPROVED PROCESS FOR PREPARING ROSUVASTATIN CACLIUM | AUROBINDO PHARMA LIMITED (IN) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008053334-A2 | AN IMPROVED PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | AUROBINDO PHARMA LIMITED (IN) | 2008-05-08 | — | — | WO | disclosed |
| WO-2006076845-A1 | PROCESS FOR PRODUCING ROSUVASTATIN CALCIUM, INTERMEDIATE FOR THE PREPARATION OF THE SAME AND PROCESS FOR PRODUCING THE INTERMEDIATE | ANHUI QINGYUN PHARMACEUTICAL AND CHEMICAL CO., LTD (CN) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228028-A1 | PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES | HMGCR, PCSK9, CYP4A11 | HMGCR 1/4885ALDH1A1 284/4885CYP3A4 43/4885 |
| US-20130066074-A1 | PROCESS FOR THE PREPARATION OF PROPENAL INTERMEDIATE AND DERIVATIVES THEREOF | NOX4, HMGCR, NOX5 | HMGCR 2/4885ALDH1A1 294/4885CYP3A4 66/4885 |
| US-20110178296-A1 | Process for preparing pyrimidine propenaldehyde | DPYD, NOX4, RPIA | HMGCR 5/4885ALDH1A1 36/4885CYP3A4 63/4885 |
| US-20100029940-A1 | PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | CACNA1E, SLC5A6, QDPR | HMGCR 67/4885ALDH1A1 1563/4885CYP3A4 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.